 Equities researchers at Morgan Stanley assumed coverage on shares of Passage Bio NASDAQ:IMRA in a report issued on Monday, Briefing.com Automated Import reports. The firm set an overweight rating and a 35.00 price target on the stock. Morgan Stanleys price objective suggests a potential upside of 122.22 from the companys current price. IMRA opened at ... 